A recent report also showed that the blockage of ER-phagy significantly promoted the anticancer effect of the ALK inhibitor brigatinib in ALK-negative cancer cells, revealing that combinational treatment with an autophagy inhibitor might be an actionable strategy for improving cancer therapy efficacy [20]. The gene discussed is ALK; the disease is cancer.